Revolution Medicines Q4 net loss widens

Revolution Medicines

25/02/2026 21:21

Overview

Oncology firm's Q4 net loss widened to $364.9 mln, driven by higher R&D expenses

Company's R&D expenses rose to $294.9 mln in Q4, up from $188.1 mln last year

Revolution Medicines maintains strong cash position with $2.0 bln as of Dec 31, 2025

Outlook

Revolution Medicines expects 2026 operating expenses between $1.6 bln and $1.7 bln

Company plans to initiate three additional Phase 3 trials in 2026

Revolution Medicines anticipates substantial enrollment completion in NSCLC trial this year

Result Drivers

CLINICAL TRIAL PROGRESS - Revolution Medicines advanced multiple Phase 3 trials, including RASolute 302 and RASolve 301, contributing to increased R&D expenses

Company press release: ID:nGNX74j6z7

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$1.86
Q4 Net Income
-$364.89 mln
Q4 Operating Expenses
$361.63 mln
Q4 Operating Income
-$361.63 mln
Q4 Pretax Profit
-$364.89 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Revolution Medicines Inc is $135.00, about 28.8% above its February 24 closing price of $104.83

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)